Report Overview

The Brazil Hepatitis Therapeutics Market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Hepatitis is a swelling or inflammation of the liver. It may occur due to drugs, alcohol use, or because certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis. Notification Disease Information System (SINAN) confirmed around 4 lakh cases of Hepatitis in brazil and around 4 thousand deaths due to viral hepatitis. Common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain.



Market Growth Drivers

Due to the increase in prevalence of viral hepatitis, higher investment in pipeline of hepatitis drugs, and increase in government initiatives to encourage patients for the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.

According to the estimates of WHO, approximately 90% of children in developing economies have been infected with the virus before reaching 10 years of age owing to poor hygiene & sanitary conditions. Brazil being an emerging economy with a large portion of rural population is prone to this estimated risk, which makes it a rising market place for therapeutics.

Market Restraints

The access to treatments of this disease has been limited to people who have a high-income level owing to high drug prices, which act as a restraining factor for this market. Lack of generic versions of HCV drugs is another reason for market restraint. If more people are able to afford the generic versions, the usage rates of its drugs are estimated to grow rapidly over the next few years.